Armstrong Lab
Principal Investigator: Scott A Armstrong
Institution: Dana-Farber Cancer Institute (Boston, MA)
Primary Subfield: Molecular & Cell Bio
Recruitment Status: Inquire for rotation/fellowship opportunities
Research Focus
Overall Program Abstract Our proposal addresses fundamental challenges in the treatment of AML, building on recent advances in drug development and new discoveries in leukemia biology, genetics, and epigenetics. We will systematically study regulators of normal and malignant hematopoiesis, leveraging expertise in BH3 profiling to identify compounds that shift cellular apoptotic threshold (Dr. Anthony Letai), by developing protein degradation as a novel tool to overcome gaps in the druggable proteome (Drs. Benjamin Ebert, Eric Fischer, and Scott Armstrong), and by discovering and developing novel agents to target a variety of dependencies in leukemia, including epigenetic programs (Dr. Armstrong and Dr. Zuzana Tothova). The Program includes productive investigators with an enduring history of collaboration. Through this program, our investigators have led research bringing FLT3 and BCL-2 inhibitors from basic science through to FDA approval for the treatment of AML, have carved out a whole new field drugging the undruggable using targeted protein degradation, and have led DOT1L and Menin inhibitors into clinical trials for patients with for KMT2A- rearranged, NPM1 mutant and NUP98-r…
Active NIH Awards
- 5P01CA066996-27: Development of Novel Therapeutic Strategies in Human Leukemias (2026)
- 5P01CA066996-27: Administrative Core (2026)
- 5P01CA066996-27: Defining mechanisms of action of Menin inhibition in AML (2026)
- 1P50CA298970-01A1: Project 1 Targeting Menin in Leukemia (2026)
- 5R01CA259273-05: Defining epigenetic mechanisms in NPM1c mutant leukemia (2025)
Explore 700+ US Biology Labs on FindBioLabs.com